Anti-Her2 / ERBB2 Antibody (Mouse Monoclonal antibody) General Information
Anti-Her2 / ERBB2 Antibody
Reacts with: Rhesus
Rhesus Her2 / ERBB2 Has cross-reactivity in ELISA with Human ErbB2 No cross-reactivity in ELISA with Human EGFR Human ERBB3 Human ERBB4 Human cell lysate (293 cell line)
Recombinant Rhesus HER2 / ErbB2 protein (Catalog#90020-K08H)
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Rhesus HER2 / ErbB2 (Catalog#90020-K08H; XP_001090430.1; Met 1-Thr 652). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
Monoclonal Mouse IgG1 Clone #10A7F7
0.2 μm filtered solution in PBS
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.
Please Note: Optimal concentrations/dilutions should be determined by the end user.
Her2 / ERBB2 Background Information
Epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD34, is a type I membrane glycoprotein, and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.
Successfully added to cart Please enter catalog numberSubmitted successfullyNetwork ErrorPlease enter your company namePlease enter your namePlease enter your emailPlease enter a valid email addressPlease enter some message